Numab Therapeutics
Pfäffikon, Switzerland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
Developing multi-specific antibody therapeutics for cancer and inflammatory diseases.
OncologyImmunology
Technology Platform
The λ-body platform enables the design and development of multi-specific, IgG-like antibodies with optimal drug-like properties for complex targeting.
Funding History
1Total raised:$50M
Series C$50M
Opportunities
Potential to expand its platform to create novel immune cell engagers and cytokine-targeting therapies for oncology and autoimmunity.
Risk Factors
Clinical development risks for complex multi-specific molecules, including managing toxicity and proving efficacy advantages over standard care.
Competitive Landscape
Faces intense competition from large biopharma and other biotechs in the multi-specific antibody space, requiring strong clinical data for differentiation.